MMR vaccine effectiveness in an outbreak that involved day-care and primary schools

Vaccine

Volumn 29, Issue 45, 2011, Pages 8024-8031

  Barrabeig, Irene ^a   Rovira, Ariadna ^a   Muñoz, Pilar ^b,c   Batalla, Joan ^b,d   Rius, Cristina ^e   Sánchez, Josep Anton ^c   Domínguez, Àngela ^b,f  

^a Generalitat of Catalonia   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d Generalitat of Catalonia   (Spain)

^e AGÈNCIA DE SALUT PÚBLICA DE BARCELONA   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Effective reproduction number; Measles; Vaccination; Vaccine effectiveness

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHILD; CLINICAL ARTICLE; DAY CARE; DISEASE TRANSMISSION; DRUG EFFICACY; EPIDEMIC; FEMALE; HUMAN; IMMUNIZATION; MALE; MEASLES; PRESCHOOL CHILD; PRIMARY SCHOOL; PRIORITY JOURNAL; SPAIN;

BASIC REPRODUCTION NUMBER; CHILD; CHILD DAY CARE CENTERS; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE OUTBREAKS; FEMALE; HUMANS; INFANT; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; RETROSPECTIVE STUDIES; SCHOOLS; SPAIN;

EID: 80053620679     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.056     Document Type: Article

References (45)

1. Anderson R.M., May R.M. Infectious diseases of humans: dynamics and control 1991, Oxford University Press, Oxford, United Kingdom.
2. Dietz K. The estimation of the basic reproduction number for infectious diseases. Stat Methods Med Res 1993, 2:23-41.
3. Gershon A.A. Measles virus. Principles and practice of infectious diseases 2010, 2229-2236. Elsevier, Philadelphia. 7th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
4. Griffin D.E. Measles virus. Fields virology 2007, 1552-1585. Wolters Kluwer, Philadelphia. 5th ed. D.M. Kniper, P.M. Howley (Eds.).
5. American Academy of Pediatrics Measles. Red Book: 2009 Report of the Committee on Infectious Diseases 2009, 444-455. American Academy of Pediatrics, Elk Grove Village, IL. 28th ed. L.K. Pickering, C.J. Baker, D.W. Kimberlin, S.S. Long (Eds.).
6. Word Health Organization. WHO vaccine-preventable diseases: monitoring system. 2010 global summary. WHO: Immunization, Vaccines and Biologicals; 2009.
7. Pan American Health Organization Measles elimination by the year 2000. EPI Newslett 1994, 16:1-2.
8. De Quadros C.A. Can measles be eradicated globally?. Bull World Health Organ 2004, 82:134-138.
9. Word Health Organization. Eliminating measles and rubella and preventing congenital rubella infection. WHO European Region strategic plan 2005-2010. Copenhagen, WHO Regional Office for Europe, 2005 [accessed 16.06.11]. http://www.euro.who.int/documE87772ent/.pdf.
10. Peltola H., Heinonen P., Valle M., Paunio M., Virtanen M., Karanko V., et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12 years, two dose vaccination program. N Engl J Med 1994, 331:1397-1402.
11. Peña-Rey I., Martínez V., Mosquera M., de Ory F., Echevarría J.E. Measles risk groups in Spain: implications for the European measles-elimination target. Vaccine 2009, 27:3927-3934.
12. Martin R., Eshevoi S., Jankovi D., Goel A., Mercer D., Laurent E. Progress toward measles elimination-European region, 2005-2008. MMWR 2009, 58:142-145.
13. Domínguez A., Torner N., Barrabeig I., Rovira A., Rius C., Caylà J., et al. Large measles outbreak in a community with high vaccination coverage. Clin Infect Dis 2008, 47:1143-1149.
14. Departament de Sanitat i Segueretat and Social L'eliminació del xarampió a Catalunya per l'any 2000 1991, Generalitat de Catalunya, Barcelona. 1st ed.
15. Domínguez A., Vidal J., Plans P., Carmona G., Godoy P., Batalla J., et al. Measles immunity and vaccination policy in Catalonia. Vaccine 1999, 17:530-534.
16. Barrabeig I., Rovira A., Rius C., Muñoz P., Soldevila N., Batalla J., et al. Effectiveness of measles vaccination for control of exposed children. Pediatr Infect Dis J 2011, 30(1):78-80. 10.1097/INF.0b013e3181f7001c.
17. WHO. Surveillance guidelines for measles, rubella and congenital rubella syndrome in the WHO European Region. Copenhagen, WHO Regional Office for Europe, 2009 [accessed 16.06.11]. http://www.euro.who.int/__data/assets/pdf_file/0018/79020/E93035.pdf.
18. Orenstein W., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63:1055-1068.
19. Halloran M.E., Haber M., Longini I.M., Struchiner C.J. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991, 133(4):323-331.
20. Halloran M.E., Struchiner C.J., Longini I.M. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997, 146(10):789-803.
21. Patel M.M., Tate J., Cortese M., Payne D.C., Armstrong G., Parashar U.D., et al. The impact of indirect benefits of vaccination on postlicensure vaccine effectiveness estimates: a scenario analysis. Vaccine 2010, 28(50):7987-7992.
22. Strebel P.M., Papania M.J., Dayan G.H., Halsey N.A. Measles vaccine. Vaccines 2008, 353-398. Saunders, Philadelphia. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
23. Becker N.G. Analysis of infectious disease data 1989, Chapman and Hall.
24. Gay N.J. The theory of measles elimination: Implications for the design of elimination strategies. JID 2004, 189(Suppl. 1):S27-S35.
25. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2011 [accessed 16.06.11]. http://cran.r-project.org/.
26. De Serres G., Gay N.J., Farrington C.P. Epidemiology of transmissible diseases after elimination. Am J Epidemiol 2000, 151:1039-1048.
27. Mossong J., Muller C.P. Estimation of the basic reproduction number of measles during an outbreak in a partially vaccinated population. Epidemiol Infect 2000, 124(2):273-278.
28. Mori N., Ohkusa Y., Ohyama T., Tanaka-Taya K., Taniguchi K., Kobayashi J.M., et al. Estimation of measles vaccine coverage needed to prevent transmission in schools. Pediatr Int 2008, 50(4):464-468.
29. King G.E., Markowitz L.E., Patriarca P.E., Dales L.G. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991, 10:883-887.
30. Ramsay M., Moffatt D., O'Connor M. Measles vaccine: a 27-year follow-up. Epidemiol Infect 1994, 112:409-412.
31. Davis R.M., Whitman E.D., Orenstein W.A., Preblud S.R., Markowitz L.E., Hinman A.R. A persistent outbreak of measles despite appropriate prevention and control measures. Am J Epidemiol 1987, 126:438-449.
32. Watson J.C., Pearson J.A., Markowitz L.E., Baughman A.L., Erdman D.D., Bellini W.J., et al. An evaluation of measles revaccination among school-entry-aged children. Pediatric 1996, 97:613-618.
33. American Academy of Pediatrics Committee of infectious diseases. Age of routine administration of the second dose of measles-mumps-rubella vaccine. Pediatric 1998, 101:129-133.
34. Viteck C.R., Aduddell M., Brinton M.J., Hoffman R.E., Redd S.C. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr Infect Dis J 1999, 18:620-623.
35. Krugman S. Present status of measles and rubella immunization in the United States: a medical progress report. J Pediatr 1971, 78:1-16.
36. Orenstein W.A., Markowitz L., Preblud Sr., Hinman A.R., Tomasi A., Bart K.J. Appropriate age for measles vaccination in the United States. Dev Biol Stand 1986, 65:13-21.
37. Marks J.S., Halpin T.J., Orenstein W.A. Measles vaccine efficacy in children previously vaccinated at 12 month of age. Pediatrics 1978, 62:955-960.
38. Leuridan E., Hens N., Hutse V., Ieven M., Aerts M., Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. Br Med J 2010, 340:C1626.
39. Johansen K., Lopalco P. Passive immunity against measles in infants: is there a need for policy changes in the European vaccination schedules?. Euro Surveill 2007, 12(9):E3-E4.
40. Markowitz L.E., Albrecht P., Rhodes P., Demonteverde R., Swint E., Maes E.F., et al. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Kaiser Permanente Measles Vaccine Trial Team. Pediatrics 1996, 97(1):53-58.
41. Word Health Organization WHO position on measles vaccines. Vaccine 2009, 27:7219-7221.
42. DECRET 219/2008, d'11 de novembre, pel qual s'estableix el calendari de vacunacions sistemàtiques. Generalitat de Catalunya, 2008 [accessed 16.06.11]. http://www.gencat.cat/diari/5257/08310104.htm.
43. Boletin epidemiologico semanal en red. Información sobre sarampion. Informe semanal de vigilancia 26 de julio de 2011. Instituto de Salud Carlos III, 2011 [accessed 08.08.11]. http://www.isciii.es/htdocs/centros/epidemiologia/boletin_red/IS-110726-WEB.pdf.
44. EUVAC.net, [accessed 16.06.11]. http://www.euvac.net/graphics/euvac/vaccination/mmr.html.
45. Ministerio de Sanidad, Política Social e Igualdad, 2011 [accessed 16.06.11]. http://www.msps.es/ciudadanos/proteccionSalud/infancia/vacunaciones/programa/vacunaciones.htm.